MedTrace Logo

Anticoagulant Treatments and Percutaneous Coronary Angioplasty

NCT00669149 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2019-05-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether adjunction of intravenous anticoagulant therapy (enoxaparin, HNF, bivalirudin) to antiaggregation with clopidogrel and aspirin improves in-hospital results of percutaneous transluminal coronary angioplasty (ptca) in selected patients.

Conditions

Interventions

DRUG

clopidogrel + aspirin

DRUG

heparin + clopidogrel + aspirin

DRUG

enoxaparin + clopidogrel + aspirin

DRUG

bivalirudin + clopidogrel + aspirin

Sponsors & Collaborators

  • Centre Hospitalier de PAU

    lead OTHER

Principal Investigators

  • Nicolas DELARCHE, MD · CH de Pau

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2013-08-03
Completion
2013-08-03

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00669149 on ClinicalTrials.gov